Evidence map›Paper›PMID 35197338›Full record

Observational studyBMJ open2022

Analysis of eGFR index category and annual eGFR slope association with adverse clinical outcomes using real-world Japanese data: a retrospective database study.

Ling Zhang, Sibylle Hauske, Yasuhisa Ono, Moe H Kyaw, Dominik Steubl, Yusuke Naito, Keizo Kanasaki

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Ling Zhang *Real World Evidence Analytics Center of Excellence, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, USA ling_3.zhang@boehringer-ingelheim.com.ORCID 0000-0003-2472-9544
Sibylle Hauske *Therapeutic Area CardioMetabolism Respiratory Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Rheinland-Pfalz, Germany.
Yasuhisa Ono *Clinical Development and Medical Affairs, Nippon Boehringer Ingelheim, Tokyo, Japan.
Moe H KyawReal World Evidence Analytics Center of Excellence, Boehringer Ingelheim Corp USA, Ridgefield, Connecticut, USA.
Dominik SteublTherapeutic Area CardioMetabolism Respiratory Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Rheinland-Pfalz, Germany.
Yusuke NaitoMedicine Division, Nippon Boehringer Ingelheim, Tokyo, Japan.
Keizo KanasakiDepartment of Internal Medicine 1, Faculty of Medicine, Shimane University, Shimane, Japan.ORCID 0000-0002-9563-502X
Boehringer Ingelheim (Germany) · DEBoehringer Ingelheim (Japan) · JPBoehringer Ingelheim (United States) · USKanazawa Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesReal-world clinical outcome data of patients with an above-normal estimated glomerular filtration rate (eGFR) and increasing eGFR over time (eGFR slope) are scarce. Although eGFR is commonly recorded, eGFR slopes are rarely used for adverse outcome risk categorisation in clinical practice. We investigated the association of above-normal/below-normal eGFR ranges and increasing/declining eGFR slopes with clinical outcomes in Japan.

designObservational cohort study.

settingPrimary and acute care hospitals; 423 centres.

participants57 452 patients aged ≥16 years with ≥3 eGFR values (latest available January 2013-December 2016) from the Japanese Medical Data Vision database were stratified into six index eGFR and six eGFR slope groups (slopes calculated using a linear mixed model). PRIMARY AND SECONDARY OUTCOME MEASURES: Time-to-event analyses of cardiovascular mortality, all-cause mortality (ACM), all-cause hospitalisation (ACH) and cardiovascular and major kidney events. eGFR and slope groups were analysed by Cox proportional hazard models with multivariable adjustment, using normal eGFR/little-to-no slope groups as reference.

resultsHigher risk of clinical outcomes was observed with declining eGFR slope groups versus the reference group; the HR (95% CI) for slope ≤-5 mL/min/1.73 m

conclusionPoorer clinical outcomes were observed not only for below-normal eGFR and declining eGFR slope groups but also for certain above-normal eGFR and increasing slope groups. eGFR and eGFR slope may, therefore, be useful for identifying patients at high risk of adverse clinical outcomes.

Indexed as

Renal Insufficiency, ChronicAdolescentGlomerular Filtration RateHumansJapanKidneyRetrospective StudiesRisk Factorsacute renal failurecardiologynephrologyrisk management

Identifiers

PMID35197338
PMCPMC8867325
OpenAlexW4213412292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.